Company profile: Janvier Labs
1.1 - Company Overview
Company description
- Provider of rodent research models and services, including immunodeficient models for studies in infectious diseases, immune system mechanisms, vaccine development, and cancer immunotherapy; humanized NXG-HIS mice with human-like immune systems for preclinical oncology and immunology; metabolic disease models; aged C57BL/6JRj mice and WISTAR rats; customized genetic model support; and SOPF/SPF colony management and logistics.
Products and services
- Humanized Models: NXG-HIS is a genetically modified, preclinical-grade mouse with a human-like immune system, used for preclinical studies in oncology and immunology
- Immunodeficient Models: Research-grade rodent models with varying immunodeficiency levels enable investigations in infectious diseases, immune system mechanisms, vaccine development, and cancer immunotherapy
- Metabolic Models: Translational-grade rodent models that mimic human metabolic diseases, including obesity and diabetes, produce translational data for research and treatment development
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Janvier Labs
Indigo Biosciences
HQ: United States
Website
- Description: Provider of nuclear receptor-focused products and services addressing therapeutic drug targets, including cell-based luciferase reporter assay kits for GPCR and nuclear receptors, Live Cell Multiplex assays to quantify live cells alongside nuclear receptor assays, INDIGlo luciferase detection reagent, environmental testing bioassays, and an ortholog assay portfolio for cross-species receptor activity comparison aiding selection of animal models for drug development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Indigo Biosciences company profile →
Elegen
HQ: United States
Website
- Description: Provider of cell-free DNA synthesis solutions, including ENFINIA DNA producing long, complex linear DNA up to 7kb with 99.999% per-base accuracy, shipped in 6 to 8 business days; high-complexity DNA synthesis for challenging sequences like long repeats and GC-rich regions, with delivery as fast as 10 business days; and an Early Access Program for pre-commercial products, including sequences longer than 15,000 base pairs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Elegen company profile →
NanoMR
HQ: United States
Website
- Description: Provider of blood diagnostic devices and an immunomagnetic capture system for rapid isolation of rare cells from complex matrices at levels of 1 cell/mL or lower, enabling simultaneous targeting of multiple cell types, including bacteria and fungi from bloodstream infections, as well as specific cells such as circulating tumor and fetal cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NanoMR company profile →
Pressure BioSciences
HQ: United States
Website
- Description: Provider of proprietary laboratory instrumentation and consumables: Pressure Cycling Technology (PCT) for controlled biomolecular interactions (cell lysis, biomolecule extraction) in biomarker discovery, drug design and forensics; BaroFold for high-pressure protein disaggregation/refolding to remove aggregates and enhance product safety and efficacy; and Ultra Shear Technology (UST) to make stable nanoemulsions, improving solubility and stability.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pressure BioSciences company profile →
Hemanext
HQ: United States
Website
- Description: Provider of blood processing, storage, and transfusion solutions. Offers Hemanext ONE, a blood container set for processing and storing red blood cells under reduced oxygen and carbon dioxide conditions to improve quality and extend shelf-life.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Hemanext company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Janvier Labs
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Janvier Labs
2.2 - Growth funds investing in similar companies to Janvier Labs
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Janvier Labs
4.2 - Public trading comparable groups for Janvier Labs
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →